1. Pink Sheet
  2. >>Product Reviews

Lingering Leqembi Question: When Should Treatment Stop?

 
• By Derrick Gingery

Several questions about the anti-amyloid product used to treat Alzheimer’s remain, which could affirm calls for more US FDA, CMS and NIH collaboration on research.

Alzheimer's puzzle
Neurology professor Randall Bateman said Alzheimer's disease treatment could be managed similar to cancer. • Source: Shutterstock

Even with apparent indicators of efficacy, clinicians still have questions about using Biogen, Inc. and Eisai Co., Ltd.’s Leqembi (lecanimab-irmb) in Alzheimer’s disease patients. Many likely require more study and some could be limiting uptake.

Leqembi has no guidance on when treatment should end, Erik Musiek, an associate neurology professor at Washington University School of Medicine, said during a Health and Human Services Department Advisory

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Post-Marketing Regulation & Studies

More from Product Reviews

FDA Adcomms Are Back: Four Cancer Drugs, COVID-19 Vaccine Formulations To Get Reviews

 
• By Sue Sutter and Bridget Silverman

The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.

Unlocking Opportunities: How To Engage With The EMA On Animal Testing Alternatives

 
• By Neena Brizmohun

The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.

Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling

 
• By Sue Sutter

Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.